Clin Infect Dis: CoVID-19 patients improved after treatment for tozhu monotomonorotic.

July 19, 2020 /PRNewswire/ -- Most patients hospitalized with COVID-19 (coronavirus) pneumonia have improved after receiving FDA-approved medications for rheumatoid arthritis, according to an observational study by Cedars-Sinai Medical CenterCompared to published reports of illness and death related to COVID-19 severe illness, patients who took tozumab had a reduced risk of inflammation, oxygen demand, blood pressure support, and deathThe single-center observational study of 27 patients, led by DrStanley Jordan, Director of Cedars-Sinai Kidney Disease and Transplant Immunology Program, was recently published in the journal Clinical Journal of Public HealthWhile the patient's treatment results were encouraging, the researchers said they were not enough to prove that the drug was safe and effective for PATIENTs with COVID-19 because they did not conduct clinical trials with the control groupThe team examined laboratory and clinical changes in 27 patients with COVID-19 pneumonia who received the immunosuppressive drug tothel supret, including oxygen levels, blood pressure-raising drug requirements, and patient survival ratesThe researchers observed an improvement in inflammatory markers and survival rates in patients who did not use toltopzumabPhoto Source: Researchers have been studying tozhuzumab for a decade, focusing on its use in rheumatoid arthritis and cancer-related cytokine stormsIn 2010, the FDA approved the drug for the treatment of rheumatoid arthritisResearchers at Cedars-Sinai found that interleukin 6 is the main cytokine elevated in patients with COVID-19, and interleukin 6 is a protein that promotes immune cell production and is also a target for tobead monovirus"Since tocilizumab inhibits leukocyte interleukin 6, we think it makes sense to test in patients with COVID-19 pneumonia," Jordan explained"Cytokines are molecules secreted by a variety of cells, including immune system cells that regulate the body's immune responseCytokine storms are a severe response that causes immune cells to overflow and attack healthy organs they are supposed to protectIn patients with COVID-19, the virus stimulates immune cells, causing damage to the lateral branches of the lungs, which can lead to blood vessel leakage and blood clottingThe patient's blood pressure dropped and the organ began to failIn the early days of the COVID-19 pandemic, medical professionals found that cytokine storms caused rapid deterioration in some patientsThe researchers learned that the key to patient survival is to prevent cytokine storms from increasing the intensity Most patients receiving tozhuzumab treatment need a ventilator to support breathing Each of them received a dose of tothozumab, which helps block the signal of cytokine leukin 6, the only destructive cytokine detected in all study patients The more interleukin6 in the body, the worse the patient's prognosis The body temperature and C-reactive protein (CRP) levels of 23 patients decreased significantly after treatment CRP levels increase when an infection is present in the body CRP levels in four patients did not decline rapidly, and three had poor prognosis Adverse events are rare, but there have been two deaths unrelated to tozhuzumab "Our observational study suggests that this drug may help reduce inflammation, oxygen needs, blood pressure support, and the risk of death," Jordan said Jordan's current research builds on his early study of tozhuzumab The study focused on the drug's potential to prevent the harmful effects of leukocyte interleukin 6 on organ transplantation, including rejection of donor organs The study found that tozhuzumab helps regulate immune response and prevent organ rejection Jordan and his colleagues are currently conducting a randomized, placebo-controlled trial of clazakizumab, another interleukin 6 blocker research drug Based on Jordan's past and current research, he is encouraged by the potential benefits of tozhuzumab for patients with COVID-19 pneumonia "Based on our preliminary results, I hope these drugs can help improve the condition of patients with COVID-19 pneumonia," Jordan said "But we don't know the results until we've completed a randomized controlled clinical trial Reference: COVID-19: Patients improve after immune-suppressant treatment Stanley C Jordan et al, Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia, Clinical EIDiseases (2020) DOI: 10.1093/cid/ciaa812.